147 related articles for article (PubMed ID: 36191992)
21. Low skeletal muscle mass predicts poor prognosis for patients with stage III cervical cancer on concurrent chemoradiotherapy.
Aichi M; Hasegawa S; Kurita Y; Shinoda S; Kato S; Mizushima T; Yokota NR; Miyagi E
Nutrition; 2023 May; 109():111966. PubMed ID: 36731243
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
[TBL] [Abstract][Full Text] [Related]
23. Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.
Liu J; Tang G; Zhou Q; Kuang W
Radiat Oncol; 2022 Aug; 17(1):142. PubMed ID: 35978412
[TBL] [Abstract][Full Text] [Related]
24. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262
[TBL] [Abstract][Full Text] [Related]
25. Long-term Outcomes of Cervical Adenocarcinoma Treated With Concurrent Chemoradiotherapy Using Paclitaxel and Cisplatin.
Arakaki Y; Ariga T; Heianna J; Shimoji Y; Nakasone T; Taira Y; Nakamoto T; Ooyama T; Kudaka W; Kaneshima I; Nishihira K; Mekaru K; Aoki Y
In Vivo; 2020; 34(5):2739-2743. PubMed ID: 32871808
[TBL] [Abstract][Full Text] [Related]
26. Maximum Standardized Uptake Value of Pelvic Lymph Nodes in [18F]-Fluorodeoxyglucose Positron Emission Tomography Is a Prognostic Factor for Para-Aortic Lymph Node Recurrence in Pelvic Node-Positive Cervical Cancer Treated With Definitive Chemoradiotherapy.
Kim DH; Kim WT; Bae JS; Ki YK; Park D; Suh DS; Kim KH; Lee JH; Lee JY; Jeon HS; Nam JH
Int J Gynecol Cancer; 2016 Sep; 26(7):1274-80. PubMed ID: 27465890
[TBL] [Abstract][Full Text] [Related]
27. Sarcopenia Is an Important Prognostic Factor in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy.
Kiyotoki T; Nakamura K; Haraga J; Omichi C; Ida N; Saijo M; Nishida T; Kusumoto T; Masuyama H
Int J Gynecol Cancer; 2018 Jan; 28(1):168-175. PubMed ID: 29040185
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy.
Ozawa Y; Nakano T; Taniyama Y; Sakurai T; Onodera Y; Kamiya K; Hikage M; Sato C; Takaya K; Konno T; Unno M; Kamei T
Esophagus; 2019 Oct; 16(4):345-351. PubMed ID: 30980203
[TBL] [Abstract][Full Text] [Related]
29. The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy.
Li X; Wei LC; Zhang Y; Zhao LN; Li WW; Ping LJ; Dang YZ; Hu J; Shi M
Int J Gynecol Cancer; 2016 Oct; 26(8):1472-9. PubMed ID: 27400321
[TBL] [Abstract][Full Text] [Related]
30. Prognostic implication of simultaneous anemia and lymphopenia during concurrent chemoradiotherapy in cervical squamous cell carcinoma.
Cho O; Chun M; Oh YT; Noh OK; Chang SJ; Ryu HS; Lee EJ
Tumour Biol; 2017 Oct; 39(10):1010428317733144. PubMed ID: 29022484
[TBL] [Abstract][Full Text] [Related]
31. Impact of Treatment Time on Chemoradiotherapy in Locally Advanced Cervical Carcinoma.
Pathy S; Kumar L; Pandey RM; Upadhyay A; Roy S; Dadhwal V; Madan R; Chander S
Asian Pac J Cancer Prev; 2015; 16(12):5075-9. PubMed ID: 26163644
[TBL] [Abstract][Full Text] [Related]
32. Concurrent weekly cisplatin versus triweekly cisplatin with radiotherapy for locally advanced squamous-cell carcinoma of the cervix: a retrospective analysis from a single institution.
Kinjyo Y; Nagai Y; Toita T; Kudaka W; Ariga T; Shimoji Y; Nakasone T; Taira Y; Arakaki Y; Nakamoto T; Wakayama A; Ooyama T; Maemoto H; Heianna J; Aoki Y
Br J Radiol; 2017 Aug; 90(1076):20170241. PubMed ID: 28707541
[TBL] [Abstract][Full Text] [Related]
33. Posttreatment squamous cell carcinoma antigen predicts treatment failure in patients with cervical squamous cell carcinoma treated with concurrent chemoradiotherapy.
Wang W; Liu X; Hou X; Lian X; Liu Z; Shen J; Sun S; Yan J; Miao Z; Wang D; Meng Q; Fu J; Zhang F; Qiu J; Hu K
Gynecol Oncol; 2019 Nov; 155(2):224-228. PubMed ID: 31500891
[TBL] [Abstract][Full Text] [Related]
34. Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study.
Ueki H; Hara T; Okamura Y; Bando Y; Terakawa T; Furukawa J; Harada K; Nakano Y; Fujisawa M
Investig Clin Urol; 2022 Jul; 63(4):415-424. PubMed ID: 35796138
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer.
Oh D; Lee JE; Huh SJ; Park W; Nam H; Choi JY; Kim BT
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):549-54. PubMed ID: 24074928
[TBL] [Abstract][Full Text] [Related]
36. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
[TBL] [Abstract][Full Text] [Related]
37. The prognostic value of histologic subtype in node-positive early-stage cervical cancer after hysterectomy and adjuvant radiotherapy.
Zhou J; Zhang WW; Wu SG; He ZY; Sun JY; Yang GF; Li FY
Int J Surg; 2017 Aug; 44():1-6. PubMed ID: 28583891
[TBL] [Abstract][Full Text] [Related]
38. The Utility of Pretreatment and Posttreatment Lymphopenia in Cervical Squamous Cell Carcinoma Patients Treated With Definitive Chemoradiotherapy.
Onal C; Yildirim BA; Guler OC; Mertsoylu H
Int J Gynecol Cancer; 2018 Oct; 28(8):1553-1559. PubMed ID: 30247248
[TBL] [Abstract][Full Text] [Related]
39. Daily low-dose Cisplatin-based concurrent chemoradiotherapy for the treatment of cervical cancer in patients 70 years or older.
Hanawa S; Mitsuhashi A; Usui H; Yamamoto N; Watanabe-Nemoto M; Nishikimi K; Uehara T; Tate S; Uno T; Shozu M
Int J Gynecol Cancer; 2015 Jun; 25(5):891-6. PubMed ID: 25811592
[TBL] [Abstract][Full Text] [Related]
40. Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma.
Yokoi E; Mabuchi S; Takahashi R; Matsumoto Y; Kuroda H; Kozasa K; Kimura T
J Gynecol Oncol; 2017 Mar; 28(2):e19. PubMed ID: 28028992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
